Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Venetoclax Added to Flu/Mel RIC Transplant for High-risk Myeloid Malignancies
NCT07044544Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of decitabine and venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) (4 cohorts), sponsored by University of Alabama at Birmingham. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Jul 2025; status: recruiting.
02
Drugs
decitabinevenetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT07044544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044544.